| Restoration of TET2 function blocks aberrant self-renewal and leukemia progression L Cimmino, I Dolgalev, Y Wang, A Yoshimi, GH Martin, J Wang, V Ng, ... Cell 170 (6), 1079-1095. e20, 2017 | 700 | 2017 |
| H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers M Seiler, A Yoshimi, R Darman, B Chan, G Keaney, M Thomas, ... Nature medicine 24 (4), 497-504, 2018 | 514 | 2018 |
| Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins SCW Lee, H Dvinge, E Kim, H Cho, JB Micol, YR Chung, BH Durham, ... Nature medicine 22 (6), 672-678, 2016 | 391 | 2016 |
| Targeting an RNA-binding protein network in acute myeloid leukemia E Wang, SX Lu, A Pastore, X Chen, J Imig, SCW Lee, K Hockemeyer, ... Cancer cell 35 (3), 369-384. e7, 2019 | 293 | 2019 |
| Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity Y Kagoya, A Yoshimi, K Kataoka, M Nakagawa, K Kumano, S Arai, ... The Journal of clinical investigation 124 (2), 528-542, 2014 | 249 | 2014 |
| Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations SCW Lee, K North, E Kim, E Jang, E Obeng, SX Lu, B Liu, D Inoue, ... Cancer cell 34 (2), 225-241. e8, 2018 | 231 | 2018 |
| Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis A Yoshimi, KT Lin, DH Wiseman, MA Rahman, A Pastore, B Wang, ... Nature 574 (7777), 273-277, 2019 | 212 | 2019 |
| Spliceosomal disruption of the non-canonical BAF complex in cancer D Inoue, GL Chew, B Liu, BC Michel, J Pangallo, AR D’Avino, T Hitchman, ... Nature 574 (7778), 432-436, 2019 | 211 | 2019 |
| Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity K Kataoka, T Sato, A Yoshimi, S Goyama, T Tsuruta, H Kobayashi, ... Journal of Experimental Medicine 208 (12), 2403-2416, 2011 | 207 | 2011 |
| Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins A Yoshimi, S Goyama, N Watanabe-Okochi, Y Yoshiki, Y Nannya, E Nitta, ... Blood, The Journal of the American Society of Hematology 117 (13), 3617-3628, 2011 | 183 | 2011 |
| Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms BH Durham, E Lopez Rodrigo, J Picarsic, D Abramson, V Rotemberg, ... Nature medicine 25 (12), 1839-1842, 2019 | 178 | 2019 |
| A role for RUNX1 in hematopoiesis and myeloid leukemia M Ichikawa, A Yoshimi, M Nakagawa, N Nishimoto, N Watanabe-Okochi, ... International journal of hematology 97, 726-734, 2013 | 161 | 2013 |
| Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells BH Durham, D Roos-Weil, C Baillou, F Cohen-Aubart, A Yoshimi, ... Blood, The Journal of the American Society of Hematology 130 (2), 176-180, 2017 | 123 | 2017 |
| Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells S Arai, A Yoshimi, M Shimabe, M Ichikawa, M Nakagawa, Y Imai, ... Blood, The Journal of the American Society of Hematology 117 (23), 6304-6314, 2011 | 118 | 2011 |
| Recurrent CDC25C mutations drive malignant transformation in FPD/AML A Yoshimi, T Toya, M Kawazu, T Ueno, A Tsukamoto, ... Nature Communications 5, 4770, 2014 | 103 | 2014 |
| Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization Z Liu, A Yoshimi, J Wang, H Cho, S Chun-Wei Lee, M Ki, L Bitner, T Chu, ... Cancer Discovery 10 (6), 806-821, 2020 | 101 | 2020 |
| Altered nuclear export signal recognition as a driver of oncogenesis J Taylor, M Sendino, AN Gorelick, A Pastore, MT Chang, AV Penson, ... Cancer discovery 9 (10), 1452-1467, 2019 | 90 | 2019 |
| Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML A Yoshimi, ME Balasis, A Vedder, K Feldman, Y Ma, H Zhang, SCW Lee, ... Blood, The Journal of the American Society of Hematology 130 (4), 397-407, 2017 | 87 | 2017 |
| Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells M Shimabe, S Goyama, N Watanabe-Okochi, A Yoshimi, M Ichikawa, ... Oncogene 28 (49), 4364-4374, 2009 | 87 | 2009 |
| Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1 DL Fei, T Zhen, B Durham, J Ferrarone, T Zhang, L Garrett, A Yoshimi, ... Proceedings of the National Academy of Sciences 115 (44), E10437-E10446, 2018 | 84 | 2018 |
Masahiro Marshall NakagawaKyoto UniversityZweryfikowany adres z kyoto-u.ac.jp
